Get AI Briefings, Transcripts & Alerts on Local & National Government Meetings — Forever.
Board committee debates AB 19 90’s limits on compounding GLP‑1 weight‑loss drugs after safety concerns and industry objections
Summary
The policy committee reviewed AB 19 90, which would impose sourcing, testing and advertising restrictions on compounded GLP‑1 products and attach mandatory penalties; board staff and public commenters split over whether the bill duplicates existing law, leaves regulatory gaps and unduly curtails pharmacist judgment. The committee opted to watch and seek author engagement.
The California State Board of Pharmacy policy committee spent the longest portion of its meeting on AB 19 90, a bill amended to curb unsafe or illicit active pharmaceutical ingredients entering the compounding supply chain—particularly for GLP‑1 weight‑loss drug compounding.
As amended, AB 19 90 would prohibit selling or distributing compounded drugs containing specified GLP‑1 or related substances unless the compounder documents pharmaceutical‑grade sourcing and testing; it would require recordkeeping, authorize board inspections of compounders and suppliers, ban misleading advertising, and make violations subject to license revocation and fines of $1,000 per dose sold or distributed.
Board staff and several members expressed concern that the bill does not apply uniformly across settings where compounding occurs, such as physician offices and medical spas, and that mandatory penalties could remove the board’s discretion in enforcement. Chair Crowley summarized staff findings, noting that “members expressed concern that the proposal could override the board’s authority and eliminate pharmacist professional judgment.” The committee did not adopt a formal position during the meeting.
Public commenters split. Sean Kim of the California Pharmacists Association told the committee CPHA opposed the bill in its current form, citing regulatory gaps and offering technical engagement with the author. “This bill not only exempts different provider types, but also leaves a regulatory gap on medical spa or physician office compounding,” Kim said, urging technical fixes.
By contrast, Gabrielle Cosell, a former FDA compounding official now working as an independent consultant, urged stronger statewide standards for GLP‑1 compounding. “Weight‑loss drug compounding is an entirely different beast than traditional compounding,” Cosell said, warning of large‑scale production, evidence of peptide‑related impurities, and immune risks that existing USP and California rules may not reliably detect. She recommended working with the sponsor to address enforcement discretion and testing requirements.
Representatives of the Alliance for Pharmacy Compounding argued the bill would primarily layer new requirements and penalties on already‑regulated pharmacies rather than improve the board’s ability to reach unregulated actors. Taniel Davis said the conduct targeted by the bill—false advertising, counterfeit or substandard ingredients, and unlawful distribution—is already illegal under federal and state law, and that overlapping requirements risk reducing patient access.
Board staff noted some bill provisions duplicate existing federal law, USP standards and recent California regulations while other provisions go beyond current standards. Members discussed options including amendments to expand the bill’s scope to non‑pharmacy compounding sites, or seeking clarifications that preserve board discretion in enforcement. After member comments and public testimony, the committee opted to ‘watch’ the measure while staff and leadership engage with the author and stakeholders on possible technical amendments.
Next steps: board staff will pursue conversations with the author’s office and stakeholders to clarify scope, enforcement discretion and applicability across practice sites before the committee revisits the measure.
